Financial, market and economic news

Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer

BRISBANE, Calif. and ST. LOUIS, Nov. 16, 2020 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Ronald Krasnow, Esq. as Chief Operating Officer. In this newly created position, Mr. Krasnow will report to Julie Hambleton, M.D., Arch Oncology’s Interim President and Chief Executive Officer.

“Ron is a legal and strategy executive with a unique breadth of experience helping lead companies through periods of growth and transition,” said Julie Hambleton, M.D., Interim President and Chief Executive Officer of Arch Oncology. “Over his career, he has led important strategic initiatives and transactions, built critical infrastructure, and rolled up his sleeves to get the job done. 2021 will be a transformational year for Arch Oncology, with multiple clinical trials for AO-176 advancing for patients in solid tumors and hematologic malignancies. We …

Full story available on

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy